UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation
NYSE:UTI • US9139151040
Current stock price
36.41 USD
-1.45 (-3.83%)
Last:
This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UTI Profitability Analysis
1.1 Basic Checks
- In the past year UTI was profitable.
- In the past year UTI had a positive cash flow from operations.
- UTI had positive earnings in each of the past 5 years.
- Each year in the past 5 years UTI had a positive operating cash flow.
1.2 Ratios
- UTI has a better Return On Assets (6.44%) than 73.97% of its industry peers.
- UTI's Return On Equity of 15.98% is fine compared to the rest of the industry. UTI outperforms 75.34% of its industry peers.
- UTI has a better Return On Invested Capital (8.69%) than 75.34% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for UTI is significantly below the industry average of 15.40%.
- The 3 year average ROIC (7.27%) for UTI is below the current ROIC(8.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROIC | 8.69% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- With a decent Profit Margin value of 6.28%, UTI is doing good in the industry, outperforming 65.75% of the companies in the same industry.
- UTI's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 8.38%, UTI is in the better half of the industry, outperforming 67.12% of the companies in the same industry.
- UTI's Operating Margin has improved in the last couple of years.
- UTI has a Gross Margin of 49.62%. This is comparable to the rest of the industry: UTI outperforms 56.16% of its industry peers.
- UTI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. UTI Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), UTI is destroying value.
- Compared to 1 year ago, UTI has more shares outstanding
- Compared to 5 years ago, UTI has more shares outstanding
- Compared to 1 year ago, UTI has an improved debt to assets ratio.
2.2 Solvency
- UTI has an Altman-Z score of 4.05. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of UTI (4.05) is better than 78.08% of its industry peers.
- UTI has a debt to FCF ratio of 6.28. This is a slightly negative value and a sign of low solvency as UTI would need 6.28 years to pay back of all of its debts.
- UTI has a better Debt to FCF ratio (6.28) than 69.86% of its industry peers.
- UTI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
- UTI has a Debt to Equity ratio (0.29) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Altman-Z | 4.05 |
ROIC/WACC1
WACC8.71%
2.3 Liquidity
- UTI has a Current Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
- UTI has a Current ratio (1.14) which is comparable to the rest of the industry.
- A Quick Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- The Quick ratio of UTI (1.14) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. UTI Growth Analysis
3.1 Past
- The earnings per share for UTI have decreased by 0.00% in the last year.
- UTI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 65.96% yearly.
- UTI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.59%.
- UTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.67% yearly.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
3.2 Future
- Based on estimates for the next years, UTI will show a small growth in Earnings Per Share. The EPS will grow by 5.89% on average per year.
- Based on estimates for the next years, UTI will show a quite strong growth in Revenue. The Revenue will grow by 8.84% on average per year.
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. UTI Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 37.54, UTI can be considered very expensive at the moment.
- UTI's Price/Earnings ratio is in line with the industry average.
- Compared to an average S&P500 Price/Earnings ratio of 27.50, UTI is valued a bit more expensive.
- With a Price/Forward Earnings ratio of 39.96, UTI can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of UTI is on the same level as its industry peers.
- When comparing the Price/Forward Earnings ratio of UTI to the average of the S&P500 Index (22.62), we can say UTI is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.54 | ||
| Fwd PE | 39.96 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as UTI.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of UTI is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 124.13 | ||
| EV/EBITDA | 18.5 |
4.3 Compensation for Growth
- The decent profitability rating of UTI may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.57
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
5. UTI Dividend Analysis
5.1 Amount
- No dividends for UTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
UTI Fundamentals: All Metrics, Ratios and Statistics
NYSE:UTI (4/23/2026, 2:10:01 PM)
36.41
-1.45 (-3.83%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04 2026-02-04/amc
Earnings (Next)05-06 2026-05-06
Inst Owners96.88%
Inst Owner Change0.96%
Ins Owners2.49%
Ins Owner Change3.2%
Market Cap2.00B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (5.52%)
Short Float %6.76%
Short Ratio4.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-103.86%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.54 | ||
| Fwd PE | 39.96 | ||
| P/S | 2.34 | ||
| P/FCF | 124.13 | ||
| P/OCF | 25.86 | ||
| P/B | 5.96 | ||
| P/tB | 6.99 | ||
| EV/EBITDA | 18.5 |
EPS(TTM)0.97
EY2.66%
EPS(NY)0.91
Fwd EY2.5%
FCF(TTM)0.29
FCFY0.81%
OCF(TTM)1.41
OCFY3.87%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.57
Graham Number11.5432 (-68.3%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROCE | 11.63% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.82% | ||
| ROICexgc | 13.27% | ||
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% | ||
| FCFM | 1.89% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Debt/EBITDA | 0.93 | ||
| Cap/Depr | 181.06% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 13.88 | ||
| Cash Conversion | 73.39% | ||
| Profit Quality | 30.06% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 4.05 |
F-Score7
WACC8.71%
ROIC/WACC1
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.6%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
What is the profitability of UTI stock?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
What is the valuation of UNIVERSAL TECHNICAL INSTITUT based on its PE and PB ratios?
The Price/Earnings (PE) ratio for UNIVERSAL TECHNICAL INSTITUT (UTI) is 37.54 and the Price/Book (PB) ratio is 5.96.
Can you provide the expected EPS growth for UTI stock?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.